Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.19 HKD
Change Today +0.02 / 1.71%
Volume 2.5M
As of 4:01 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

shenzhen neptunus interlng-h (8329) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/21/15 - $1.37
52 Week Low
12/19/14 - $0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHENZHEN NEPTUNUS INTERLNG-H (8329)

Related News

No related news articles were found.

shenzhen neptunus interlng-h (8329) Related Businessweek News

No Related Businessweek News Found

shenzhen neptunus interlng-h (8329) Details

Shenzhen Neptunus Interlong Bio-technique Company Limited researches and develops, produces, sells, and distributes gene engineering drugs and preventive biological products in the People’s Republic of China. It operates through Manufacturing and Selling of Medicines, Sales and Distribution of Medicines and Healthcare Products, and Provision of R & D Services of Modern Biological Technology segments. The company offers herbal medicine, generic, transfusion, and antitumor drugs under the Neptunus and Interlong brand names. Its primary products include recombinant human interferon a-2b for injection, recombinant human interleukin-2 for injection, and subunit influenza vaccine. The company produces chemical medicines; wholesales and retails packaging materials and pre-packaged foods; sells and distributes medicines and healthcare products; and researches and develops biological reagents and in-vitro diagnostic reagents. It sells its products in approximately 20 provinces in China; and serves approximately 500 medical organizations. The company is based in Shenzhen, the People’s Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Co., Ltd.

1,460 Employees
Last Reported Date: 03/30/15

shenzhen neptunus interlng-h (8329) Top Compensated Officers

Chief Executive Officer, General Manager and ...
Total Annual Compensation: CNY632.0K
Executive Chairman, Compliance Officer, Chair...
Total Annual Compensation: --
Executive Director
Total Annual Compensation: CNY480.0K
Compensation as of Fiscal Year 2013.

shenzhen neptunus interlng-h (8329) Key Developments

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported turnover of RMB 150,879,000 compared to RMB 149,067,000 a year ago. Profit from operations was RMB 21,036,000 compared to RMB 23,378,000 a year ago. Profit before taxation was RMB 18,327,000 compared to RMB 21,330,000 a year ago. Profit for the period attributable to owners of the company was RMB 10,961,000 or 0.65 cents per basic and diluted share compared to RMB 12,986,000 or 0.77 cents per basic and diluted share a year ago. During the Quarter, other revenue of the Group increased significantly as compared with the corresponding period last year, which was mainly due to the increase in interest income on bank deposits and government subsidy income.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. to Report Q1, 2015 Results on May 08, 2015

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. announced that they will report Q1, 2015 results on May 08, 2015

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd., Board Meeting, May 08, 2015

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd., Board Meeting, May 08, 2015., at 10:30 China Standard Time. Agenda: To consider the unaudited consolidated first quarterly results of the company and its subsidiaries for the three months ended 31 March 2015; to consider the payment of an interim dividend (if any); to consider the closure of the register of members (if necessary); and to transact any other business.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8329:HK $1.19 HKD +0.02

8329 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8329.
View Industry Companies

Industry Analysis


Industry Average

Valuation 8329 Industry Range
Price/Earnings 51.3x
Price/Sales 2.5x
Price/Book 3.1x
Price/Cash Flow 51.3x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHENZHEN NEPTUNUS INTERLNG-H, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at